WO2002048400A1 - Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1 - Google Patents
Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1 Download PDFInfo
- Publication number
- WO2002048400A1 WO2002048400A1 PCT/JP2001/010813 JP0110813W WO0248400A1 WO 2002048400 A1 WO2002048400 A1 WO 2002048400A1 JP 0110813 W JP0110813 W JP 0110813W WO 0248400 A1 WO0248400 A1 WO 0248400A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- side effect
- expression
- effect caused
- irinotecan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167005073A KR101651391B1 (ko) | 2000-12-12 | 2001-12-10 | Ugt1a1 효소에 의해 그 자체 또는 중간 대사물이 대사되는 화합물의 투여에 따른 부작용 발현 리스크를 예측하는 방법 |
JP2002550114A JP4447835B2 (ja) | 2000-12-12 | 2001-12-10 | Ugt1a1酵素によってそれ自体又は中間代謝物が代謝される化合物の投与による副作用発現リスクを予測する方法 |
AT01270625T ATE469966T1 (de) | 2000-12-12 | 2001-12-10 | Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung |
KR1020037007790A KR101651287B1 (ko) | 2000-12-12 | 2001-12-10 | Ugt1a1 효소에 의해 그 자체 또는 중간 대사물이대사되는 화합물의 투여에 따른 부작용 발현 리스크를예측하는 방법 |
DE60142309T DE60142309D1 (de) | 2000-12-12 | 2001-12-10 | On einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung |
EP01270625A EP1352970B1 (en) | 2000-12-12 | 2001-12-10 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabloized per se by ugt1a1 or whose intermediate is metabolized by the enzyme |
AU2002221112A AU2002221112A1 (en) | 2000-12-12 | 2001-12-10 | Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme |
US10/459,729 US20040058363A1 (en) | 2000-12-12 | 2003-06-12 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
US11/543,055 US20070082357A1 (en) | 2000-12-12 | 2006-10-05 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
US12/453,291 US20090263818A1 (en) | 2000-12-12 | 2009-05-06 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
US13/026,719 US20110151474A1 (en) | 2000-12-12 | 2011-02-14 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by ugt1a1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000376756 | 2000-12-12 | ||
JP2000-376756 | 2000-12-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/459,729 Continuation US20040058363A1 (en) | 2000-12-12 | 2003-06-12 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002048400A1 true WO2002048400A1 (fr) | 2002-06-20 |
Family
ID=18845576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010813 WO2002048400A1 (fr) | 2000-12-12 | 2001-12-10 | Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1 |
Country Status (10)
Country | Link |
---|---|
US (4) | US20040058363A1 (ja) |
EP (1) | EP1352970B1 (ja) |
JP (2) | JP4447835B2 (ja) |
KR (2) | KR101651391B1 (ja) |
CN (1) | CN100374575C (ja) |
AT (1) | ATE469966T1 (ja) |
AU (1) | AU2002221112A1 (ja) |
DE (1) | DE60142309D1 (ja) |
ES (1) | ES2346848T3 (ja) |
WO (1) | WO2002048400A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004027088A2 (en) * | 2002-09-20 | 2004-04-01 | UNIVERSITé LAVAL | Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug |
JP2007509604A (ja) * | 2003-10-06 | 2007-04-19 | ノバルティス アクチエンゲゼルシャフト | 薬剤誘発下痢の予測のためのバイオマーカー |
WO2007055261A1 (ja) * | 2005-11-10 | 2007-05-18 | The New Industry Research Organization | Ugt1a1遺伝子多型の検査法 |
WO2008066136A1 (en) * | 2006-11-30 | 2008-06-05 | Arkray, Inc. | Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same |
WO2016006532A1 (ja) * | 2014-07-07 | 2016-01-14 | 株式会社日立製作所 | 薬効分析システム及び薬効分析方法 |
US11692216B2 (en) | 2015-02-17 | 2023-07-04 | Yamaguchi University | Method for assisting prediction of risk of occurrence of side effect of irinotecan |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
WO2002059375A2 (en) * | 2001-01-26 | 2002-08-01 | University Of Chicago | Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage |
US20040203034A1 (en) * | 2003-01-03 | 2004-10-14 | The University Of Chicago | Optimization of cancer treatment with irinotecan |
US7807350B2 (en) | 2003-05-30 | 2010-10-05 | The University Of Chicago | Methods for predicting irinotecan toxicity |
US20090247475A1 (en) * | 2004-03-05 | 2009-10-01 | The Regents Of The University Of California | Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
GB2432365A (en) * | 2005-11-18 | 2007-05-23 | Dxs Ltd | A nucleic acid molecule for detecting polymorphisms in the UGT1A1 promoter |
JP4884899B2 (ja) * | 2006-09-19 | 2012-02-29 | 東洋鋼鈑株式会社 | イリノテカンの副作用の発生危険度を判定する方法およびそのためのキット |
KR200452078Y1 (ko) * | 2009-03-10 | 2011-01-28 | 주식회사 디아이디 | 벽지샘플북의 손잡이 |
JP2011250726A (ja) * | 2010-06-01 | 2011-12-15 | Toyo Kohan Co Ltd | イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット |
CN102816858B (zh) * | 2012-09-06 | 2014-02-19 | 上海源奇生物医药科技有限公司 | 一种检测ugt1a1基因型的引物和探针、及其试剂盒 |
CN107043808A (zh) * | 2017-01-19 | 2017-08-15 | 上海赛安生物医药科技有限公司 | Ugt1a1基因多态性检测引物肽核酸及其试剂盒 |
CN109371127A (zh) * | 2018-10-22 | 2019-02-22 | 江苏美因康生物科技有限公司 | 一种同时快速检测ugt1a1*6型与ugt1a1*28型基因多态性的试剂盒及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
WO1997032042A2 (en) * | 1996-03-01 | 1997-09-04 | The University Court Of The University Of Dundee | Drug trial assay system |
PT1071710E (pt) * | 1998-04-15 | 2007-01-31 | Serono Genetics Inst Sa | Sequência genómica da proteína activadora da 5- lipoxigenase ( flap), seus marcadores polimórficos e métodos para a detecção de asma |
EP1084271A2 (en) * | 1998-05-07 | 2001-03-21 | Axys Pharmaceuticals, Inc. | Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene |
US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
-
2001
- 2001-12-10 DE DE60142309T patent/DE60142309D1/de not_active Expired - Lifetime
- 2001-12-10 KR KR1020167005073A patent/KR101651391B1/ko active IP Right Grant
- 2001-12-10 WO PCT/JP2001/010813 patent/WO2002048400A1/ja active Application Filing
- 2001-12-10 AT AT01270625T patent/ATE469966T1/de not_active IP Right Cessation
- 2001-12-10 ES ES01270625T patent/ES2346848T3/es not_active Expired - Lifetime
- 2001-12-10 KR KR1020037007790A patent/KR101651287B1/ko active IP Right Grant
- 2001-12-10 AU AU2002221112A patent/AU2002221112A1/en not_active Abandoned
- 2001-12-10 CN CNB01822542XA patent/CN100374575C/zh not_active Expired - Lifetime
- 2001-12-10 EP EP01270625A patent/EP1352970B1/en not_active Expired - Lifetime
- 2001-12-10 JP JP2002550114A patent/JP4447835B2/ja not_active Expired - Lifetime
-
2003
- 2003-06-12 US US10/459,729 patent/US20040058363A1/en not_active Abandoned
-
2006
- 2006-10-05 US US11/543,055 patent/US20070082357A1/en not_active Abandoned
-
2009
- 2009-05-06 US US12/453,291 patent/US20090263818A1/en not_active Abandoned
- 2009-05-29 JP JP2009129753A patent/JP4616919B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-14 US US13/026,719 patent/US20110151474A1/en not_active Abandoned
Non-Patent Citations (5)
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004027088A2 (en) * | 2002-09-20 | 2004-04-01 | UNIVERSITé LAVAL | Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug |
WO2004027088A3 (en) * | 2002-09-20 | 2004-08-19 | Univ Laval | Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug |
JP2007509604A (ja) * | 2003-10-06 | 2007-04-19 | ノバルティス アクチエンゲゼルシャフト | 薬剤誘発下痢の予測のためのバイオマーカー |
WO2007055261A1 (ja) * | 2005-11-10 | 2007-05-18 | The New Industry Research Organization | Ugt1a1遺伝子多型の検査法 |
JPWO2007055261A1 (ja) * | 2005-11-10 | 2009-04-30 | 財団法人新産業創造研究機構 | Ugt1a1遺伝子多型の検査法 |
WO2008066136A1 (en) * | 2006-11-30 | 2008-06-05 | Arkray, Inc. | Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same |
US8357516B2 (en) | 2006-11-30 | 2013-01-22 | Arkray, Inc. | Primer set for amplification of UGT1A1 gene, reagent for amplification of UGT1A1 gene containing the same, and the uses thereof |
JP5307538B2 (ja) * | 2006-11-30 | 2013-10-02 | アークレイ株式会社 | Ugt1a1遺伝子増幅用プライマーセット、それを含むugt1a1遺伝子増幅用試薬およびその用途 |
US9175272B2 (en) | 2006-11-30 | 2015-11-03 | Arkray, Inc. | Probes for detection of UGT1A1 gene, reagent containing the same, and the uses thereof |
WO2016006532A1 (ja) * | 2014-07-07 | 2016-01-14 | 株式会社日立製作所 | 薬効分析システム及び薬効分析方法 |
JP2016018321A (ja) * | 2014-07-07 | 2016-02-01 | 株式会社日立製作所 | 薬効分析システム及び薬効分析方法 |
US11692216B2 (en) | 2015-02-17 | 2023-07-04 | Yamaguchi University | Method for assisting prediction of risk of occurrence of side effect of irinotecan |
Also Published As
Publication number | Publication date |
---|---|
KR20030053064A (ko) | 2003-06-27 |
KR20160031023A (ko) | 2016-03-21 |
JP4616919B2 (ja) | 2011-01-19 |
EP1352970A4 (en) | 2004-08-25 |
US20040058363A1 (en) | 2004-03-25 |
ATE469966T1 (de) | 2010-06-15 |
EP1352970B1 (en) | 2010-06-02 |
US20110151474A1 (en) | 2011-06-23 |
CN100374575C (zh) | 2008-03-12 |
CN1547613A (zh) | 2004-11-17 |
DE60142309D1 (de) | 2010-07-15 |
AU2002221112A1 (en) | 2002-06-24 |
JPWO2002048400A1 (ja) | 2004-04-15 |
JP2009195247A (ja) | 2009-09-03 |
EP1352970A1 (en) | 2003-10-15 |
KR101651287B1 (ko) | 2016-08-26 |
KR101651391B1 (ko) | 2016-08-25 |
US20070082357A1 (en) | 2007-04-12 |
JP4447835B2 (ja) | 2010-04-07 |
US20090263818A1 (en) | 2009-10-22 |
ES2346848T3 (es) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002048400A1 (fr) | Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1 | |
WO2003038123A3 (en) | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene | |
WO2001047944A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2000029623A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2001040521A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2001048245A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2001079230A3 (en) | Haplotypes of the ugt1a1 gene | |
WO1998022586A3 (en) | HUMAN POLYHOMEOTIC 2 (hph2) ACTS AS A TUMOR SUPPRESSOR | |
WO2001023603A3 (en) | Human fmo3 gene mutations and polymorphisms, and uses thereof | |
WO2002026764A3 (en) | Haplotypes of the ccr6 gene | |
WO2000029622A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2001077363A3 (en) | Haplotypes of the impdh2 gene | |
WO2003023063A1 (fr) | Methode d'estimation du risque d'apparition de diabetes | |
WO2001051670A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2001058914A3 (en) | Haplotypes of the interleukin 15 gene | |
WO2001038586A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
WO2002010454A3 (en) | Haplotypes of the alas2 gene | |
WO2002026766A3 (en) | Haplotypes of the sstr4 gene | |
WO2002053579A3 (en) | Haplotypes of the fmo2 gene | |
WO2002022652A3 (en) | Haplotypes of the slc18a2 gene | |
WO2002012562A3 (en) | Haplotypes of the pla2g1b gene | |
WO2002038587A3 (en) | Haplotypes of the grm8 gene | |
WO2001087903A3 (en) | Haplotypes of the acaa1 gene | |
WO2001092279A3 (en) | Haplotypes of the aldh5 gene | |
WO2002032930A3 (en) | Haplotypes of the scya21 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002550114 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037007790 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10459729 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037007790 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001270625 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01822542X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001270625 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |